4月4日 - ** 以色列药物开发商 Galmed Pharmaceuticals GLMD.O 股价下跌 5.5% 至 1.38 美元
** 马克西姆集团（Maxim Group）将其评级从 "买入 "下调至 "持有"，并取消PT评级。
** 下调 GLMD 的评级，原因是前进道路和战略定位不明确--Maxim
** 马克西姆表示，GLMD 可能还需要筹集资金才能开始临床试验；在目前的市场条件下，融资可能会很困难，而且会大幅摊薄成本。
** 截至上次收盘，GLMD 年累计跌幅超过 52
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.